Screening Strategies in Drug Discovery – News and Features

This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.

A new study has measured the toxicity of several types of PFAS, better known as “forever chemicals,” when mixed together in the environment and in the human body.

A UCLA team created a biobank of sarcoma organoids from 126 patients, enabling rapid drug screening. The organoids retained tumor characteristics, allowing identification of effective FDA-approved treatments for 59% of samples.

Girls exposed to certain EDCs may be more likely to start puberty early, according to new research. Early puberty is associated with an increased risk of psychosocial problems, obesity, diabetes, cardiovascular disease and breast cancer.

High concentrations of organic micropollutants caused the death of fish, mussels and snails in the Oder river in 2022 by exacerbating the lethal effects of an algal toxin.

University of Vienna researchers developed MolCompass, a tool that identifies blind spots in machine learning models used for chemical risk assessment. The tool aims to increase transparency and confidence in computational models.

Researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method introduces a new sulfur fluoride exchange (SuFEx) reagent that allows for highly controlled production of crucial sulfur-based molecules.

In this interview, Tola Olorunnisola, senior vice president and general manager at Avantor, delves into how AI and automation could put the Lab of the Future within our grasp, enabling scientific breakthroughs and revolutionizing the drug development process.

The ability to obtain pure proteins is essential for developing drugs, creating vaccines and understanding biological processes. In this article, we discuss what a typical protein purification protocol involves and the various techniques used.

At SLAS Europe 2024, Technology Networks had the pleasure of speaking with Jeroen Verheyen, CEO of Semarion, to discuss their award-winning work and how technological innovations advance research.